In the context of his work for CSHL spin-off Helicon Pharmaceuticals, which was developing a drug to enhance memory, Jerry Yin notes that “looking for a drug that enhances memory is a marathon. It’s not a sprint.” He raises the question of whether it’s more effective in the long term to invest money in a targeted way, in a single company trying to develop a specific drug, or whether an equivalent amount of resources and work invested more broadly in basic research might not have resulted in us knowing more about this particular problem.
